Mind Medicine (MNMD) has released an update.
Mind Medicine (MindMed), a biopharmaceutical company specializing in treatments for brain health disorders, is set to discuss its latest findings for the MM120 drug in treating Generalized Anxiety Disorder (GAD) during an upcoming conference call and webcast. The discussion will focus on 12-week Phase 2b trial results, showcasing the safety, efficacy, and durability of MM120, as well as the progress of the oral dissolving tablet formulation towards crucial clinical trials.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
